Smith Brendan 4
4 · CRISPR Therapeutics AG · Filed Feb 22, 2022
Insider Transaction Report
Form 4
Smith Brendan
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-02-18+30,000→ 30,000 totalExercise: $58.29Exp: 2032-02-18→ Common Shares (30,000 underlying) - Award
Restricted Stock Units
2022-02-18+15,300→ 15,300 total→ Common Shares (15,300 underlying)
Footnotes (3)
- [F1]This option was granted on February 18, 2022 with respect to 30,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022.
- [F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F3]This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.